Rationale Several laboratories have conducted placeboc o n t r o l l e d d r u g c h a l l e n g e s t u d i e s w i t h 3 , 4 -methylenedioxymethamphetamine (MDMA), providing a unique source of data to examine the reliability of the acute effects of the drug across subject samples and settings. We examined the subjective and physiological responses to the drug across three different laboratories and investigated the influence of prior MDMA use. Methods Overall, 220 healthy volunteers with varying levels of previous MDMA experience participated in laboratorybased studies in which they received placebo or MDMA orally (1.5 mg/kg or 125-mg fixed dose) under double-blind conditions. Cardiovascular and subjective effects were assessed before and repeatedly after drug administration. The studies were conducted independently by investigators in Basel, San Francisco, and Chicago. Results Despite methodological differences between the studies and differences in the subjects' drug use histories, MDMA produced very similar cardiovascular and subjective effects across the sites. The participants' prior use of MDMA was inversely related to feeling "Any Drug Effect" only at sites testing more experienced users.
Introduction
Several laboratories across the world have conducted controlled studies administering 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") to healthy volunteers (de la Torre et al. 2000; Liechti et al. 2001; Tancer and Johanson 2003; Dumont et al. 2009; Bedi et al. 2010; Kirkpatrick et al. 2012) . These studies provide a unique source of data regarding possible sources of variability in drug responses, such as drug use history or environmental setting. However, the extent to which responses to the drug are consistent across different laboratory sites is not known. The literature is replete with failures to replicate results, especially in behavioral studies (Pashler et al. 2012; Yong 2012; Smith et al. 2013) , including recent investigations of acute amphetamine effects (Hart et al. 2013) . Therefore, reports of consistencies across studies and across laboratories are important and greatly strengthen the conclusions. In this study, we examined the quality and magnitude of responses to MDMA in healthy volunteers obtained in three different laboratories.
One factor known to influence an individual's response to drugs is past drug use. With MDMA, there is some evidence that chronic tolerance develops to its "positive" subjective effects (Solowij et al. 1992; Verheyden et al. 2003; Parrott 2005; Sumnall et al. 2006) . However, apparent decreases in effects may result from changes in the purity of MDMA tablets over time or geographical location (Sherlock et al. 1999; Baggott et al. 2000; Spruit 2001; Parrott 2004; Morefield et al. 2011) . Nevertheless, there is evidence of chronic tolerance to the behavioral effects of MDMA in studies with rats and rhesus monkeys (Zacny et al. 1990; Frederick et al. 1998; Fantegrossi et al. 2004; Baumann et al. 2008) , suggesting that tolerance may also occur in humans.
In this report, we examine responses to a single dose of MDMA in participants whose self-reported lifetime use of ecstasy/MDMA ranged from 0 to 200 separate occasions of use. We examined the drug's effects on heart rate, blood pressure, and self-reported subjective effects using data conducted at the California Pacific Medical Center Research Institute in San Francisco (SF), the University of Chicago (Chicago), and the University Hospital Basel (Basel). Some of the data were previously published (Harris et al. 2002; Bedi et al. 2010; Hysek and Liechti 2012) ; some are as yet unpublished (SF, Chicago) . The studies at the three sites had both methodological commonalities and differences (Table 1) . At all laboratories, healthy adults received comparable, moderate doses of MDMA (1.5 mg/kg or 125-mg fixed dose) and placebo under double-blind conditions, and the studies used similar outcome measures. However, participants at the sites differed in nationality (Swiss, US), native language (German, English), and drug use history (no prior use to high levels of use), and there were minor procedural differences including instructions, drug expectancies, and environmental conditions during sessions (e.g., presence or absence of researchers, participants in bed or ambulatory). Also, some of the studies included additional test sessions with other doses of MDMA, an active control drug, or a pretreatment drug.
Overall, these methodological differences across sites provide a rigorous test of the reliability of the subjective and behavioral effects of MDMA. Moreover, most previously published studies with MDMA present aggregated data, whereas the current report provides individuallevel analysis allowing us to examine the role of MDMA use history in acute response to the drug.
Methods and materials

Participants
At all three sites, healthy young adults were screened for psychiatric and medical problems. Inclusion criteria were similar across laboratories, with some differences in current drug use. Participants at all three sites included current alcohol and nicotine users, but current smoking was limited in Basel to less than seven cigarettes/day and in Chicago to less than ten cigarettes/day. Current marijuana users were excluded in the Basel laboratory but not in Chicago or SF. Participants in Chicago and SF, but not in Basel, had to report some previous use of MDMA. Participants at all sites were required to test negative for alcohol and other drugs of abuse before each experimental session. Participants were excluded if they had a current Axis I disorder, including substance dependence (DSM-IV), or any cardiovascular or neurological disorder that would increase risk for study participation.
The studies were conducted according to the principles expressed in the Declaration of Helsinki. All participants provided written informed consent. Although ethical considerations vary from site to site, depending on the local cultural milieu and on aspects of the specific laboratories, the protocols were fully approved by the Ethics Committee of the Canton of Basel, Switzerland and by the Institutional Review Boards at the University of California, San Francisco, the California Pacific Medical Center Research Institute, or the University of Chicago Medical Center.
Procedure, dependent measures, and drug Before each session, participants provided urine (SF, Chicago, Basel) and breath samples (SF, Chicago) to confirm abstinence from drugs and alcohol, and women were tested for pregnancy. Placebo or MDMA (dispensed by weight of 1.5 mg/kg [SF and Chicago] or fixed dose of 125 mg [Basel] ) was administered orally, under double-blind conditions, between 8 and 11 a.m. Dependent measures, including heart rate and blood pressure and mood states, were obtained at baseline and at repeated intervals for several hours after capsule administration. Mood states were measured using visual analog scales (VAS), with the following descriptors: "Do you feel any drug effect?" "Do you like the drug effects?" "Do you feel Stimulated?" "Anxious?" "Closeness to others?" Each adjective was presented with a 100-mm line labeled "not at all" at one end and "extremely" at the other end.
Data analysis
To evaluate whether the effects of MDMA differed between laboratories, peak cardiovascular measures and subjective effects were analyzed using multilevel linear models (MLMs Figure 1 shows the time course of the effects of MDMA at the three sites, on a representative subjective measure ("Drug Liking") and a cardiovascular measure (systolic blood pressure). Across sites, the drug produced similar increases in heart rate and blood pressure (Fig. 2, top panels; p=0.15-1.00) and it produced similar reports on most subjective responses. Participants in the three sites did not differ in their peak ratings of "Any Drug Effect," "Drug Liking," and "Stimulated" (Fig. 2 , bottom panels; some data not shown; p=0.07-1.00) after MDMA administration. Some minor site differences were noted. Chicago participants reported greater peak ratings of "Anxious" after MDMA administration compared to SF and Basel participants, and SF participants reported greater peak ratings of "Closeness to Others" compared to Basel participants (Fig. 2, p<0 .05 for all comparisons). Interestingly, following placebo, Chicago participants reported significantly greater peak ratings of Any Drug Effect and Drug Liking compared to SF and Basel participants (Fig. 2,  p<0 .01 for all comparisons). Additionally, Basel participants exhibited lower peak systolic and diastolic pressure on placebo sessions, compared to those from other laboratories (Fig. 2 
Discussion
We showed that acute responses to MDMA are highly stable across different testing sites, and in different subject samples. The drug produced very similar increases in heart rate, blood pressure, and subjective effects across the three laboratories, despite a number of methodological differences. Additionally, the data provide modest evidence for the development of tolerance to some effects of the drug among heavier users of the drug. The fluctuations that can be expected across different testing sites failed to influence the subjective and cardiovascular responses to the drug. Across the three sites, participants between Basel and the other two sites; †p<0.05, significant difference between Chicago and the other two sites; §p<0.05, significant difference between SF and Basel differed in language, culture, age, and past MDMA use and probably other drug use and other unmeasured demographic characteristics, as well. Different experimenters monitored the subjects under varying conditions (in a hospital bed, in a recreational environment), and the instructions to subjects and subjects' expectancies varied across settings. Some subjects were tested in the context of larger studies involving other drug administration. The pharmacological effects of the drug were consistent and robust. These findings may be compared to data with other drugs: the effects of amphetamines appear to be stable across contexts (Zacny et al. 1992; de Wit et al. 1997) , whereas the effects of hallucinogens depend significantly on the context in which they are used (Studerus et al. 2012) .
Despite the marked similarities in responses to MDMA across sites, there were some differences in subjective drug response across sites. That is, SF participants reported relatively greater ratings of Closeness to Others and Chicago participants reported greater ratings of Anxious following MDMA administration. These differences may reflect either procedural differences or subtle differences in the subject samples. SF and Basel participants received MDMA in a social setting (i.e., researchers were always present in the room), whereas Chicago participants were tested alone. Given that the psychosocial context can influence and enhance subjective responses to drugs (Carlin et al. 1972; Pliner and Cappell 1974; Doty and de Wit 1995; de Wit et al. 1997; Kirkpatrick and de Wit 2013) , it is possible that this social setting enhanced the "prosocial" and reduced the "negative" effects of MDMA. Additionally, MDMA-induced feelings of interpersonal closeness may result from a learned association between the drug and the social setting in which it is used. Thus, the SF participants, who had more MDMA experience, may have felt more prosocial effects than the Basel participants because of their conditioning history. Interestingly, however, ratings of Closeness to Others were negatively related to prior MDMA use in the SF group (at trend level: p=0.07), suggesting that tolerance may develop to this effect.
There was also a minor difference between the sites in placebo response: Basel participants exhibited lower blood pressure after placebo compared to those from other laboratories, possibly because they remained at rest in hospital beds throughout the session. Additionally, Chicago participants reported greater drug liking after placebo compared to those from other laboratories, perhaps because of subtle aspects of instructions and blinding procedures (e.g., SF and Basel participants were explicitly told that they would receive either MDMA or placebo, whereas Chicago participants were informed that they could receive a stimulant, sedative, opioid, cannabinoid, or placebo). Thus, it is possible that the expectancy of receiving any drug affected placebo responses in the Chicago population. We found some evidence that greater prior use of MDMA was associated with lesser ratings of feeling Any Drug Effect. This finding appears consistent with epidemiological evidence suggesting that more experienced users of MDMA feel lesser effects of the drug (Solowij et al. 1992; Verheyden et al. 2003; Parrott 2005; Sumnall et al. 2006 ). To our knowledge, the current study is the first to report a relationship between MDMA use history and acute response to a known, standardized MDMA dose. Thus, these data provide the strongest support for the idea that repeated use of MDMA leads to an attenuation of the subjective drug experience. Surprisingly, participants in Basel, who had little or no prior experience, appeared to show the opposite pattern. The subjects in Basel typically had no experience with MDMA before participating in the studies, and so their responses reflected only their first, second, or third experience with the drug, ever. It is possible that subjects come to identify the drug effect more accurately across these initial experiences. In any case, however, the present findings provide little support for the idea that the first response to this drug is dramatically greater than subsequent uses.
The negative relation between prior drug use and ratings of feeling Any Drug Effect in the SF and Chicago sites is consistent with chronic pharmacological tolerance, as has been reported in animal studies (Zacny et al. 1990; Frederick et al. 1998; Fantegrossi et al. 2004; Baumann et al. 2008) . Surprisingly, this relationship only reached significance with this single measure, suggesting that it may have resulted from factors other than pharmacological tolerance. For example, heavier users of one drug are likely also to use relatively high doses of other potent recreational drugs, which may lessen their assessments of this moderate dose of MDMA, administered in a laboratory environment. It is also possible that tolerance develops in the natural ecology but is less detectable in the novel laboratory setting because of differences in the doses used, the time of day of use, or the context of use (Winstock et al. 2001; Degenhardt et al. 2004) . That is, tolerance may be environment-specific. Another possibility is that the relationship between prior use and acute drug effects was limited to the measure of Any Drug Effect because this is a global rating that encompasses the full range of perceived drug effects; high variability on other measures may reduce the sensitivity to detect relationships. Nevertheless, the current results suggest that chronic tolerance may develop to some MDMA-related subjective effects, and this would be an interesting topic for future research.
Unlike some previous reports, we did not observe any gender differences in MDMA-related subjective or cardiovascular effects (e.g., Verheyden et al. 2002; Liechti et al. 2001) . For example, Liechti and colleagues (2001) observed that women reported greater subjective responses to the drug, but lesser cardiovascular responses. However, other studies have not detected these differences (Dumont et al. 2008 ). The differences between these studies could be related to differences in subjective-effect measures (e.g., perceptual effects and thought disturbances versus mood), subject samples, or hormonal states in women at the time of testing (White et al. 2002) . Future studies might systematically investigate the influence of menstrual cycle phase on the acute subjective, physiological, and behavioral effects of MDMA.
In conclusion, we found that an acute dose of MDMA, administered under controlled conditions, produced very similar effects at three quite different laboratory sites. This indicates that the drug's effects are robust and reproducible. We also found that previous exposure to MDMA or ecstasy was related to a measure of subjective drug response, providing some evidence of tolerance to the drug's effects. Thus, overall the current data provide modest evidence for chronic tolerance to the effects of MDMA and provide little evidence that the initial experiences are dramatically greater than subsequent experiences. These findings extend our understanding of the repeatability and pharmacological profile of MDMA. Similar studies with other drugs might reveal the specific and common effects of drugs studied across sites and study populations.
